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Background: The aim of this study is to evaluate the effect of gender and menopause in cardiometabolic risk in a
type 2 diabetes mellitus (T2DM) population, based on classical and non-traditional markers.
Methods: Seventy four volunteers and 110 T2DM patients were enrolled in the study. Anthropometric data, blood
pressure, body mass index (BMI), waist circumference (WC) and the following serum markers were analyzed:
glucose, Total-c, TGs, LDL-c, Oxidized-LDL, total HDL-c and large and small HDL-c subpopulations, paraoxonase 1
activity, hsCRP, uric acid, TNF-α, adiponectin and VEGF.
Results: Non-diabetic women, compared to men, presented lower glycemia, WC, small HDL-c, uric acid, TNF-α and
increased large HDL-c. Diabetes abrogates the protective effect of female gender, since diabetic women showed
increased BMI, WC, small HDL-c, VEGF, uric acid, TNF-α and hsCRP, as well as reduced adiponectin, when compared
with non-diabetic. In diabetic females, but not in males, WC is directly and significantly associated with TNF-α, VEGF,
hsCRP and uric acid; TNF-α is directly associated with VEGF and hsCRP, and inversely with adiponectin.
Postmenopausal females presented a worsen cardiometabolic profile, viewed by the increased WC, small HDL-c,
VEGF, uric acid, TNF-α and hsCRP. In this population, WC is directly and significantly associated with TNF-α, VEGF,
hsCRP; TNF-α is directly associated with VEGF; and uric acid is inversely associated with large HDL-c and hsCRP with
adiponectin, also inversely.
Conclusions: Diabetes abrogates the protective effect of gender on non-diabetic women, and postmenopausal
diabetic females presented worsen cardiometabolic risk, including a more atherogenic lipid sketch and a pro-
inflammatory and pro-angiogenic profile. The classical cardiovascular risk factors (CVRFs) fail to completely explain
these differences, which are better clarified using “non-traditional” factors, such as HDL-c subpopulations, rather
than total HDL-c content, and markers of inflammation and angiogenesis, namely TNF-α, hsCRP, uric acid and VEGF.
Multi-therapeutic intervention, directed to obesity, atherogenic lipid particles and inflammatory mediators is
advisory in order to efficiently prevent the serious diabetic cardiovascular complications.
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Cardiovascular disease (CVD) is a major public health
problem worldwide and the leading cause of death in
Portugal and in most industrialized and developing coun-
tries [1,2]. This mortality of cardiovascular (CV) cause ap-
pears to be increasing in countries where type 2 diabetes
mellitus (T2DM) is prevalent; therefore, diabetic patients
are associated with a risk 2 to 4 times higher of CVD devel-
opment, accounting for 50-80% of deaths as well as for the
increased morbidity and loss of quality of life in these pa-
tients [3,4]. Apart from being per se a risk factor for CVD,
T2DM is often associated with a higher prevalence of other
important risk factors, including hypertension, obesity, in-
sulin resistance, microalbuminuria and dyslipidaemia [5,6],
a multifactorial condition, often referred as metabolic syn-
drome, which is responsible for the high CV morbidity and
mortality in those patients [7]. Pharmacological treatment
is crucial for delaying the progression of diabetes, yet it re-
mains inadequate in preventing the increased risk of CVD
in patients with T2DM, especially women [6].
The CV risk seems to be different for men and women.
The apparent cardioprotective effects of endogenous es-
trogens seem to prevent CVD in premenopausal women,
when compared with age-matched men; however, follow-
ing menopause and the consequent loss of hormonal ef-
fects, gender-based differences in CVD are reduced [8,9].
The increased CVD risk after menopause seems to be
associated with the emergence of the features of metabolic
syndrome [10], but the precise causes remain to be fully
elucidated. Obesity is an independent risk factor for
macrovascular disease across sexes [11]; however, despite
higher incidence of obesity in premenopausal women,
rates of macrovascular disease are lower than in men.
Interestingly, this sex difference, which normally vanishes
after menopause, is rapidly lost in premenopausal T2DM
patients, with CVD reaching 2- to 5-fold higher rates than
in non-diabetic women [12]. In fact, women with T2DM,
compared with age-matched non-diabetic women, exhibit
several-fold higher rates of death related to coronary ar-
tery disease (CAD), with event rates nearly identical to
those observed in T2DM men [13]. Traditional cardiovas-
cular risk factors (CVRFs) cannot completely account for
these sex differences in cardiovascular mortality [14]. So,
it seems clear that more studies are needed to understand
the precise influence of gender and menopause in the risk
for CVD, especially in diabetic patients, in order to
achieve effective preventative and disease management
strategies to reduce the CVD risk associated with the dis-
ease, particularly in postmenopausal women.
As the leading cause of death in T2DM patients, the
CVD is a complex phenomenon, which involves meta-
bolic, lipidic, oxidative, inflammatory, as well as genetic
factors. Beyond hyperglycemia, a number of other com-
mon risk factors may contribute to CVD in diabeticwomen. Low plasma levels of high-density lipoprotein
cholesterol (HDL-c) have been largely recognized as a
risk factor for coronary heart disease (CHD) [15,16] and
they are a common feature of the dyslipidaemia linked
to diabetes and insulin resistance [17]. Recent findings
suggest that monitoring the type of HDL particles (carry
distinct and specific proteins or lipids and differentiated
by their density and size – large, intermediate and
small), rather than their total quantity, is a more reason-
able way of determining the CV risk, suggesting that dif-
ferent subpopulations may have a different role in
reverse cholesterol transport and CVD risk protection
[18]. In fact, some recent studies have been reporting
that large HDL levels are reduced in patients with CAD
compared to healthy subjects and inversely related to
both disease severity and progression of coronary lesions
[19]. Paraoxonases (PONs) are enzymes from the HDL,
and have been indicated as one of the best candidates
for the protective activity of HDL against CVD develop-
ment, namely protection against LDL oxidation [20]. In
fact, oxidized LDL (Ox-LDL) and HDL are indeed antag-
onists in the development of CVD [21]. Several studies
have shown a strong positive correlation between the
lower levels of HDL and the development of atheroscler-
osis, but their role in the determination of CVR in gen-
der and menopause in a diabetic population remains to
be clarified.
Chronic inflammation is currently viewed as a key fac-
tor in the development of atherosclerosis, contributing
to raise the overall CV risk, namely in diabetic patients.
An inflammatory imbalance, as manifested by increased
pro-inflammatory cytokines, such as the tumor necrosis
factor alpha (TNF-α), increased C-reactive protein
(hsCRP), and/or reduced levels of anti-inflammatory
and anti-atherogenic mediators, such as adiponectin,
have been considered a key factor for the increased
CVR in some pathologies [22,23], deserving more atten-
tion in respect to the gender and menopause, mainly in
diabetes. Similar importance is now attributed to the
phenomenon of angiogenesis, which has the vascular
endothelial growth factor (VEGF) as the key biomarker,
which has been suggested as a novel promising target
for T2DM treatment [24]. Another new marker that de-
serves our attention is the uric acid; although uric acid
can act as an antioxidant, excess serum accumulation is
often associated with several conditions, and has been
suggested as an independent risk factor for carotid ath-
erosclerosis in patients with type 2 diabetes [25]. Fur-
thermore, a prospective follow-up study showed that
hyperuricemia is associated with higher risk of T2DM,
independent of obesity, dyslipidemia and hypertension
[26]. Thus, it would be important to understand its influ-
ence concerning gender and menopause modulation of CV
risk, mainly in diabetes.
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and menopause on CV risk in a diabetic population,
using both traditional and new non-traditional markers.
Materials and methods
Subjects and ethical consideration
As control group 74 volunteers, including 39 males and
35 females (16 pre- and 19 postmenopausal), were ran-
domly recruited during the performance of routine la-
boratory analysis in a clinical laboratory. Participants
were not using exogenous steroids, not taking any
medication and did not declare any disease. The study
involved also 110 age and gender-matched T2DM pa-
tients, including 57 males and 53 females (8 pre- and 45
postmenopausal). Type 2 diabetes mellitus was diag-
nosed in the Diabetes and Metabolic Diseases Unit from
the Coimbra Hospital Centre (EPE), according to the
European Guidelines. Diabetes patients were treated
with the following medication: a) Insulin and/or oral
antidiabetic drugs (OAD): biguanides monotherapy (14),
sulfonylurea monotherapy (3), combination of two OAD
(25), combination of three or more OAD (32), combination
of OAD and insulin (20), insulin monotherapy (16); b)
antidyslipidemic drugs: statins monotherapy (39), fibrates
monotherapy (4), combination of two antidyslipidemic
drugs(7) and without antidyslipidemic drugs (60); c)
antihypertensive drugs, mainly angiotensin-converting en-
zyme inhibitors, angiotensin receptor blockers, calcium
channel blockers and diuretics, distributed by the following
protocols: monotherapy (18), combination of two antihy-
pertensive drugs (34), combination of three or more
antihypertensive drugs (35) and without antihypertensive
drugs (23). Menopausal status (pre- and postmenopausal
women) was defined by the questionnaire and menstrual
status was self-reported during the interviews. Pregnant
women and people with age <16 or >75 years were ex-
cluded from this study. The study was performed in agree-
ment with the code of ethics of the World Medical
Association (Declaration of Helsinki) for human studies
and received authorization from the local ethics commit-
tee, as well as from all the participants by signing a written
informed consent.
Data and blood collection
The following data was obtained from each subject by
trained personnel: weight and height (without shoes and
wearing light outdoor clothing) were measured in order
to calculate body mass index (BMI), waist circumference
(WC), as well as systolic and diastolic blood pressure
(SBP and DBP), the latter of which were assessed in the
sitting position after a 5-min rest. Blood samples were
collected by venipuncture from the subjects after an
overnight fasting period, via both EDTA-containing tubes
and tubes without anticoagulant, in order to obtainplasma, buffy-coat and serum, and processed within 2
hours of collection. Aliquots were immediately stored at
−80°C until assayed.Assays
Lipid profile
Serum total cholesterol (Total-c), HDL cholesterol (HDL-
c), LDL cholesterol (LDL-c) and triglycerides (TGs) were
analyzed on a Hitachi 717 analyser (Roche Diagnostics)
using standard laboratorial methods. Total-c reagents and
TGs kit were obtained from bioMérieuxW sa (Lyon,
France). HDL-c Plus and LDL-c Plus tests were obtained
from F. Hoffmann-La Roche Ltd (Roche Diagnostics Div.,
Basel, Switzerland). Serum glucose levels were measured
using a Glucose Oxidase commercial kit (Sigma, St. Louis,
Mo, USA). Plasma concentration of Ox-LDL was evalu-
ated by using a standard commercial enzyme-linked
immunoassay (Oxidized LDL ELISA, Mercodia, Uppsala,
Sweden).HDL subpopulations assay
Subpopulations were separated and quantified using a
Lipoprint kit from Quantimetrix Corp. (Redondo Beach,
CA, USA). The assay involves a polyacrylamide gel elec-
trophoresis assay and a complete Lipoprint System for
data acquisition and quantification of Large, Intermedi-
ate, and Small subpopulations of HDL.PON1 paraoxonase activity
Was assessed spectrophotometrically and expressed in
nmol of pnitrophenol/ml/min. In brief, paraoxonase
activity was measured by adding serum to 1 mL Tris/
HCl buffer (100 mmol/L, pH 8.0) containing 2 mmol/L
CaCl2 and 5.5 mmol/L paraoxon (O,O-diethyl-O-p-
nitrophenylphosphate; Sigma Chemical Co). The rate of
generation of p-nitrophenol was determined at 412 nm,
37°C, via the use of a continuously recording spectro-
photometer (Beckman DU-68).Serum inflammatory, angiogenic and endothelial markers
Serum adiponectin, TNF-α and VEGF contents were
assessed using QuantikineW enzyme-linked immunoas-
says kits from R&D Systems (Minneapolis, USA); serum
intercellular adhesion molecule 1 (iCAM1) levels were
evaluated by using an Elisa kit from Abcam (Cambridge,
MA, USA); high-sensitivity C-reactive protein (hsCRP)
was evaluated by immunoturbidimetry, using commer-
cially available kits (CRP [latex] High-Sensitivity, Roche
Diagnostics); uric acid was analyzed on a Hitachi 717
analyser (Roche Diagnostics) using standard laboratory
methods.
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Statistical analysis was performed by using the IBM
Statistical Package for Social Sciences (SPSS) for Win-
dows, version 20.0, (SPSS Inc., Chicago, IL, USA). The
distribution of continuous variables was analyzed using
Kolmogorov-Smirnov tests, to assess significant depar-
tures from Normality. Comparisons between groups were
performed using the Independent Samples t-test and the
Mann–Whitney test. Adjustment of statistical differences
for confounding factors was performed using analysis of
covariance (ANCOVA). The association between categor-
ical variables was analyzed using Pearson’s test. Statistical
significance was accepted at P less than 0.05.
Results
Anthropometric data and general characterization of
populations
The demographic and anthropometric data of control
volunteers and diabetic patients (male, female, pre- and
postmenopausal women) are summarized in Tables 1
and 2. Seventy four control volunteers were enrolled in
the study: 39 (52.70%) males and 35 (47.30%) females
(16 in the premenopausal and 19 in the postmenopausal
stage). One hundred and ten type 2 diabetic patients
were recruited: 57 (51.82%) males and 53 (48.18%) fe-
males (8 in the premenopausal and 45 in the postmeno-
pausal stage). Diabetic patients, both male and female,
presented significantly higher values of glycemia, BMI,
WC and uric acid when compared with the gender and
age-matched controls (Table 1 and Figure 1D). SystolicTable 1 Data from the diabetic population and age and gend
Control group
Parameters Male (n = 39) Female (n = 35) P M
Age (years) 59.97 ± 1.02 54.71 ± 1.68 0.100 5
Gender (%M/%F) 52.70 47.30 —
BMI (Kg/m2) 27.89 ± 0.72 27.09 ± 0.71 0.704 3
WC (cm) 101.32 ± 1.75 92.26 ± 1.96 0.003 11
SBP (mmHg) 145.28 ± 3.08 143.74 ± 3.98 0.010 13
DBP (mmHg) 87.10 ± 1.54 87.76 ± 2.06 0.654 7
Glycemia (mmol/L) 5.58 ± 0.08 5.12 ± 0.09 0.000 9
HbA1c (%) — — — 8
Total-c (mmol/L) 5.71 ± 0.15 5.30 ± 0.14 0.121 4
TGs (mmol/L) 1.28 ± 0.08 1.08 ± 0.06 0.118 1
LDL-c (mmol/L) 3.70 ± 0.15 3.36 ± 0.13 0.222 2
Ox-LDL (U/L) 52.65 ± 2.60 33.23 ± 1.92 0.000 3
Non-HDL-c (mmol/L) 4.28 ± 0.15 3.86 ± 0.14 0.110 3
PON1 activity 519.66 ± 18.63 449.05 ± 21.66 0.034 42
Results are presented as media ± SEM. Independent samples T-test and Mann–Whi
for age and BMI (ANCOVA) when adequate (when p<0.05): for age when comparing
vs control (both for male and for female). BMI, body mass index; HbA1c, glycated h
low-density lipoprotein cholesterol; Ox-LDL, oxidized low-density lipoprotein; TGs, tand diastolic blood pressure was significantly lower in
the male and female diabetic subjects, which is in agree-
ment with the antihypertensive medication taken. Re-
garding differences between males and females in each
population, the female controls presented significantly
reduced values of glycemia and SBP, when compared
with the age-matched control males, while the female dia-
betic patients presented significantly higher of glycated
hemoglobin (HbA1c), when compared with the age-
matched diabetic males (Table 1). BMI and WC values
should not be compared between different sexes as the
normal range values are distinct for man and woman.
Concerning the pre and postmenopausal populations
of controls and diabetics females, premenopausal dia-
betic patients presented significantly higher values of
glycemia and a trend (although non-statistically signifi-
cant) to increased BMI and WC, when compared with
the premenopausal control women. Postmenopausal dia-
betic women presented additional changes. Indeed, when
compared with the age-matched postmenopausal control
females, diabetic presented significantly increased gly-
cemia, BMI and WC (Table 2 and Figure 2D). Diastolic
blood pressure was significantly lower in the diabetic fe-
males (both pre and postmenopausal) vs the control ones.
Concerning differences before and after menopause in
each population, postmenopausal control women showed
increased glycemia and SBP versus premenopausal, while
postmenopausal diabetic females presented increased SBP
without changes on BMI or WC when compared with
premenopausal diabetic patients (Table 2 and Figure 2D).er-matched controls
Diabetic group Diabetic vs control (P)
ale (n = 57) Female (n = 53) P Male Female
8.88 ± 1.34 60.49 ± 1.42 0.524 0.453 0.013
51.82 48.18 — — —
0.37 ± 0.65 30.12 ± 0.67 0.788 0.013 0.002
0.36 ± 1.70 104.02 ± 2.05 0.020 0.000 0.000
6.86 ± 2.95 137.53 ± 3.61 0.942 0.002 0.000
3.54 ± 1.69 72.74 ± 1.77 0.745 0.000 0.000
.70 ± 0.48 10.69 ± 0.59 0.191 0.000 0.000
.13 ± 0.25 9.20 ± 0.30 0.007 — —
.75 ± 0.15 4.89 ± 0.15 0.526 0.000 0.129
.85 ± 0.15 1.99 ± 0.15 0.406 0.002 0.000
.69 ± 0.14 2.69 ± 0.14 0.996 0.000 0.012
2.58 ± 1.78 32.42 ± 1.84 1.000 0.000 0.401
.50 ± 0.16 3.56 ± 0.16 0.635 0.004 0.257
6.01 ± 20.27 490.17 ± 30.31 0.077 0.004 0.780
tney test for normalized and non-normalized samples, respectively. P adjusted
female diabetic vs female control subjects; for BMI when comparing diabetic
emoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-c,
riglycerides; Total-c, total cholesterol; WC, waist circumference.
Table 2 Data from the female diabetic population and age-matched controls: menopause influence
Female control group Female diabetic group Diabetic vs control (P)
Parameters Pre-M (n = 16) Post-M (n = 19) P Pre-M (n = 8) Post-M (n = 45) P Pre-menopausal Post- menopausal
Age (years) 45.63 ± 1.12 62.37 ± 1.35 0.000 43.88 ± 1.29 63.44 ± 1.20 0.000 0.349 0.345
BMI (Kg/m2) 26.93 ± 1.21 27.21 ± 0.85 0.472 29.43 ± 2.44 30.24 ± 0.67 0.578 0.221 0.013
WC (cm) 91.38 ± 2.86 93.06 ± 2.75 0.575 100.57 ± 4.93 104.66 ± 2.27 0.081 0.103 0.000
SBP (mmHg) 132.69 ± 5.62 153.56 ± 4.61 0.004 120.38 ± 7.22 140.58 ± 3.91 0.048 0.187 0.113
DBP (mmHg) 84.25 ± 3.20 90.89 ± 2.52 0.175 72.25 ± 3.14 72.82 ± 2.02 0.519 0.027 0.000
Glycemia (mmol/L) 4.92 ± 0.10 5.31 ± 0.14 0.038 10.80 ± 1.65 10.67 ± 0.64 0.832 0.000 0.000
HbA1c (%) — — — 9.03 ± 1.08 9.23 ± 0.30 0.477 — —
Total-c (mmol/L) 5.08 ± 0.16 5.48 ± 0.21 0.364 4.68 ± 0.44 4.93 ± 0.16 0.725 0.313 0.090
TGs (mmol/L) 1.02 ± 0.08 1.13 ± 0.10 0.455 1.51 ± 0.31 2.08 ± 0.17 0.467 0.066 0.003
LDL-c (mmol/L) 3.21 ± 0.17 3.47 ± 0.19 0.514 2.71 ± 0.35 2.69 ± 0.15 0.997 0.164 0.007
Ox-LDL (U/L) 29.13 ± 1.76 36.46 ± 2.98 0.044 34.83 ± .58 31.89 ± 1.61 0.993 0.897 0.339
Non-HDL-c (mmol/L) 3.68 ± 0.17 4.01 ± 0.20 0.390 3.36 ± 0.45 3.60 ± 0.17 0.781 0.236 0.243
PON1 activity 415.66 ± 26.78 477.17± 32.14 0.420 443.94 ± 31.40 498.39 ± 35.22 0.089 0.527 0.916
Results are presented as media ± SEM. Independent samples T-test and Mann–Whitney test for normalized and non-normalized samples, respectively. P adjusted
for age and BMI (ANCOVA) when adequate (when p<0.05): for age when comparing pre vs postmenopausal women (both in control and diabetic subjects); for
BMI when comparing postmenopausal diabetic women vs postmenopausal control subjects. BMI, body mass index; HbA1c, glycated hemoglobin; SBP, systolic
blood pressure; DBP, diastolic blood pressure; LDL-c, low-density lipoprotein cholesterol; Ox-LDL, oxidized low-density lipoprotein; TGs, triglycerides; Total-c, total
cholesterol; WC, waist circumference.
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Classical lipid profile
As previously mentioned, diabetic patients were under
antidyslipidemic therapy, which justify some of the data
obtained for the classic lipid profile. Therefore, male dia-
betic patients presented significantly lower serum concen-
trations of Total-c, LDL-c, Ox-LDL-c and non-HDL-c
when compared with the male control subjects. Identical
profile was encountered between female diabetic and
control individuals, with significantly lower serum
contents of LDL-c and a trend to reduced Total-c, Ox-
LDL-c and non-HDL-c for the female diabetic women
(Table 1). However, TGs and HDL-c concentrations
showed a distinct profile, most probably due to the
expected lower impact of antidyslipidemic medication
on these parameters of lipid profile. In agreement, male
diabetic patients presented significantly higher values of
TGs and lower of HDL-c, when compared with con-
trols, and female patients presented also increased TGs
contents and a trend to reduced HDL-c, when com-
pared with female controls (Figure 1A). Regarding dif-
ferences between males and females in each population,
only a reduced Ox-LDL-c concentration was found in
the females of the control group (vs males), without
changes between females and males in the diabetic
population (Table 1).
Concerning the pre and postmenopausal populations
of control and diabetic females, premenopausal patientspresented significantly higher values of TGs when com-
pared with premenopausal controls, while postmeno-
pausal diabetic showed reduced LDL-c and increased
TGs (Table 2), without changes on the other classical
lipid profile parameters, vs controls. Regarding differ-
ences between pre and postmenopausal women in each
population, only an increased Ox-LDL-c concentration
was found in the postmenopausal control women
(vs premenopausal), without changes between pre and
postmenopausal diabetic women (Table 2).
Paraoxonase activity and HDL-c subpopulations
Unchanged values of paraoxonase activity were found
between diabetic and control women, while a reduced
activity was encountered in male diabetic patients when
compared with the male control subjects. Regarding dif-
ferences within the groups, female controls presented
significantly lower values of PON1 activity (vs male),
without changes between male and female diabetic pa-
tients (Table 1). No changes were encountered between
pre and postmenopausal women in the control and in
the diabetic populations, as well as between the diabetic
and matched controls (before or after menopause).
In relation to HDL-c subpopulations, diabetic women
presented significantly lower concentration of large HDL-c
and higher of small HDL-c, when compared with female
controls; male patients presented unchanged values of
large HDL-c and significantly lower of small HDL-c, when
compared with male controls. Furthermore, while un-
changed values were found between diabetic male and
Figure 1 Gender effect on control and diabetic populations. Serum total HDL-c (A), large HDL-c (B), small HDL-c (C), waist circumference (D),
VEGF (E), uric acid (F), adiponectin (G), TNF-α (H) and hsCRP (I), in male and female diabetic patients and controls. Results are presented as mean
± SEM. *p<0.05, **p<0.01 and ***p<0.001.
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large and reduced small HDL-c concentrations were found
in the female controls when compared with males
(Figure 1B and 1C).
In respect to menopause influences, unchanged values
were found between pre and postmenopausal status for
large and small HDL in the control population, as wellas in the diabetic patients. However, postmenopausal
diabetic women presented significantly reduced large
HDL-c and increased small HDL-c concentrations, when
compared with postmenopausal controls, while un-
changed values for both large and small HDL-c subpop-
ulations were encountered between premenopausal
diabetic patients and controls (Figure 2B and 2C).
Figure 2 Menopause effect on control and diabetic populations. Serum total HDL-c (A), large HDL-c (B), small HDL-c (C), waist circumference
(D), VEGF (E), uric acid (F), adiponectin (G), TNF-α (H) and hsCRP (I), in pre and postmenopausal diabetic patients and controls. Results are
presented as mean ± SEM. *p<0.05, **p<0.01 and ***p<0.001.
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lesion
The diabetic women presented increased levels of serum
VEGF, uric acid, hsCRP and TNF-α and reduced of
adiponectin, when compared with the control females,
while male diabetic patients showed increased serum
uric acid and hsCRP concentrations and reduced TNF-α
and adiponectin, when compared with male control sub-
jects (Figure 1E, 1F, 1G, 1H and 1I). Regarding
differences between male and female, diabetic womenpresented significantly increased levels of serum VEGF,
hsCRP and adiponectin (versus male patients), while
control females presented significantly reduced values of
uric acid, TNF-α and adiponectin, when compared with
male controls (Figure 1F, 1G, 1H and 1I).
Concerning menopause influence, postmenopausal
diabetic patients presented significantly increased serum
uric acid, hsCRP, TNF-α and VEGF contents, and un-
changed of adiponectin, when compared with the post-
menopausal controls. Premenopausal patients presented
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trations, and unchanged of TNF-α and adiponectin, ver-
sus the premenopausal controls (Figure 2E, 2F, 2G, 2H
and 2I). Regarding differences before and after meno-
pause, control postmenopausal subjects only presented
increased serum hsCRP contents, versus premenopausal
control women, while diabetic postmenopausal patients
showed increased TNF-α and reduced hsCRP contents
(Figure 2E, 2F, 2G, 2H and 2I).
Analysis of correlations between markers of CV risk in
diabetic patients
The values of waist circumference in the diabetic female
population were positively and significantly correlated
with TNF-α (r=0.340, p=0.040), VEGF (r=0.414, p=0.011),
hsCRP (r=0.448, p=0.022) levels, while in the male dia-
betic population none of these correlations were statisti-
cally significant and the associations of WC with VEGF
and with hsCRP showed an inverse profile (r=0.264,
p=0.105; r=−0.227, p=0.164 and r=−0.222, p=0.408, re-
spectively) (Figure 3A, 3B and 3C). However, waist cir-
cumference was positively and significantly correlated
with uric acid in males (r=0.339, p=0.035) but not in fe-
males (r=0.250, p=0.261) (Figure 3D). Furthermore, also
in the female diabetic subjects, serum TNF-α concentra-
tions showed a positive and significant correlation withFigure 3 Main correlations in male and female diabetic patients. Corr
and uric acid (D); between TNF-α and VEGF (E) and between hsCRP and adVEGF (r=0.282, p=0.044) levels and hsCRP contents,
which presented an inverse and significant correlation
with adiponectin (r=−0.590, p=0.004) concentrations,
which were less evident and statistically non-significant in
the male diabetic patients (r=−0.027, p=0.853; r=−0.164,
p=0.490) (Figure 3E and 3F).
Regarding the postmenopausal diabetic population,
once again, there was a strong positive and significant
correlation between WC and TNF-α (r=0.354, p=0.046),
WC and VEGF (r=0.446, p=0.014) and WC and hsCRP
(r=0.496, p=0.019) levels (Figure 4A, 4B and 4B). Serum
uric acid presented an inverse and significant correlation
with large HDL-c (r=−0.405, p=0.045) (Figure 4D). Add-
itionally, in the same population of postmenopausal dia-
betic patients, serum TNF-α concentrations showed a
positive and significant correlation with VEGF (r=0.302,
p=0.040) levels and hsCRP contents presented an inverse
and significant correlation with adiponectin (r=−0.534,
p=0.018) concentrations (Figure 4E and 4F). No correlation
analysis was performed for premenopausal diabetic pa-
tients due to the short number of individuals in this sub-
population, which makes unfeasible this type of analysis.
Discussion
The risk for coronary artery disease (CAD), the main
cause of death in women, increases after menopause [9].elation between waist circumference and TNF-α (A), VEGF (B), hsCRP (C)
iponectin (F).
Figure 4 Main correlations in postmenopausal diabetic patients. Correlation between waist circumference and TNF-α (A), VEGF (B) and
hsCRP (C); between uric acid and large HDL-c (D); between TNF-α and VEGF (E) and between hsCRP and adiponectin (F).
Mascarenhas-Melo et al. Cardiovascular Diabetology 2013, 12:61 Page 9 of 14
http://www.cardiab.com/content/12/1/61Premenopausal women are at lower risk for CAD than
postmenopausal and than men [8,9]. Although previous
studies have spotlighted the effects of estrogens, no con-
clusive evidence has proven their role in reducing the in-
cidence of CVD [27]. Indeed, hormone replacement
therapy for the menopausal women does not confer car-
diovascular protection according to the Women’s Health
Initiative trial [28]. Therefore, estrogen deficiency may
indirectly contribute to the increased risk of CVD in
postmenopausal women. Some studies suggest that the
cardiovascular effects usually attributed to menopause
are merely a consequence of the older age of menopausal
women [29]. In contrast, others demonstrated that meno-
pause is associated with a modest increase in total fatness
and an accelerated accumulation of central body fat that
exceeds changes normally attributed to the aging process
[30]. Indeed, the transition from premenopausal to post-
menopausal status is associated with the emergence of
various risk factors for metabolic syndrome and the rising
incidence of CAD during menopause occurs in parallel
with an increase in the incidence of T2DM [10]. The
presence of diabetes increases the risk for CAD in both
premenopausal and postmenopausal women and probably
counteracts the protective effect of estrogens on the vas-
culature [31,32], so that premenopausal diabetic women
show the same risk for CAD as men and 2- to 5-foldhigher rates than in non-diabetic women [12,13]. In
addition, CAD is considered as one of the most important
complications of DM in both sexes. Hypertension and
dyslipidemia are risk factors for CAD among diabetic
patients and it is well established that patients with dia-
betes have more extensive and more rapidly progressive
CAD than non-diabetic subjects [12,13]. Several studies
showed a 2 to 4-fold higher prevalence of atheroscler-
otic disease in diabetic compared to non-diabetic indi-
viduals [33,34]. Diabetic women have greater mortality
risk from CAD than non-diabetic men and women [35].
Since the traditional CVRFs cannot completely account
for these sex differences in cardiovascular mortality,
more research is pivotal to understand the precise influ-
ence of gender and menopause in the risk for CVD, es-
pecially in diabetic patients.
This study has compared the effects of gender and
menopause on cardiovascular parameters/markers in a
diabetic population under antidiabetic, antidyslipidemic
and antihypertensive medication, compared with matched
controls. Male and female subpopulations, from both
groups, presented identical age, percentage of males/
females and BMI. Female waist circumference normal
range is distinct between males and females cannot be dir-
ectly compared. As expected, diabetic patients (from both
genders) presented higher values of glycemia, BMI and
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controls. However, systolic and diastolic blood pressure
were significantly reduced in the diabetic patients (male
and female), confirmative of the antihypertensive medica-
tion taken. The data of the control subjects shows slight
higher values of blood pressure that might be related with
the age of these individuals, which were chosen to be age-
matched with the diabetic ones in order to minimize the
influence of this factor in the analysis. Additionally, lower
values of total-c, LDL-c, Ox-LDL-c and non-HDL-c were
found in the diabetic patients when compared with the
control subjects. However, increased contents of serum
TGs and reduced of HDL-c were found for the diabetic
subjects. This classical lipid profile is in agreement with
what could be expected with the type of antidyslipidemic
therapy practiced, since statins, the main class of drugs
used, have less impact on TGs and HDL-c than on total-
cholesterol and LDL-c. Despite the pharmacological and
behavioral interventions directed to control risk factors
for CVD in diabetic patients, the incidence of CVD re-
mains alarmingly high. Dyslipidaemia, which is associated
with increased CVD mortality in diabetic individuals [36],
is among the most important modifiable risk factors.
There is now a wide variety of antidyslipidemic drugs
[37,38]; however, with the increasing combination of
risk factors commonly found in several CV diseases,
including in T2DM, the control of dyslipidaemia is not
enough, requiring a more effective modulation of HDL-c,
which remains only slightly modifiable with the current
pharmacological arsenal [39,40]. Our study in diabetic pa-
tients under antidyslipidemic therapy reinforces the need
of better intervention on HDL-c.
Concerning other markers of cardiovascular/metabolic
risk, the male diabetic patients presented increased
hsCRP, uric acid and reduced adiponectin concentra-
tions, while the female diabetic subjects also presented
increased hsCRP and uric acid, as well as TNF-α and
VEGF, with reduced adiponectin levels. Thus, both the
male and female diabetic patients showed impaired
markers of cardiometabolic risk, which is accompanied by
increased waist circumference. This pro-inflammatory
profile, a key factor in the development of atherosclerosis,
is in agreement with other studies which have reported
increased pro-inflammatory mediators, such as TNF-α
and hsCRP, and reduced levels of anti-inflammatory and
anti-atherogenic mediators, such as adiponectin [21,41].
Furthermore, adiponectin levels of diabetic woman were
negatively associated with hsCRP, in agreement with a re-
cent study [42]. Additionally, increase in hsCRP levels was
greater in women than men, in agreement with previous
data [43], and might be due to the significantly increased
concentration in the premenopausal diabetic women.
Hence, even though the reduced blood pressure and some
of the traditional marker of lipid profile (total-c, LDL-cand non-HDL-c), which is in agreement with the medi-
cation taken, the diabetic patients presented obesity and
visceral adiposity, accompanied by markers of low-grade
inflammation, and uncorrected TGs and HDL-c con-
tents, which are less modifiable with the most used
antidyslipidemic agents (mainly statins). Collectively,
the impaired parameters might be viewed as predictors/
markers of an increased cardiometabolic risk in this dia-
betic population.
Regarding the differences among men and women, in
the control population females presented lower glycemia,
unchanged total-c, TGs, LDL-c and non-HDL-c, together
with reduced Ox-LDL, TNF-α, adiponectin and uric acid.
However, lower PON1 activity was found in women,
which might be explained by the men’s compensatory in-
crement of PON1 activity against the pro-oxidative profile
(viewed by the significantly higher Ox-LDL contents). In
agreement, despite identical total HDL-c concentrations
in both subgroups, the quality of HDL was better in fe-
male, as they presented higher contents of large HDL-c
and reduced of small HDL-c. Therefore, collectively, this
data is indicative of a better cardiometabolic profile and
lower CV risk in non-diabetic females when compared
with males. However, when the subpopulations of diabetic
patients are compared, the differences between male and
female are significantly reduced. Indeed, almost all the
parameter of reduced risk found in the control females
(vs control males) are no long different, and women even
presented higher values of HbA1c, VEGF and hsCRP,
despite the higher adiponectin concentration, which might
be viewed as the exception of this clearly worse car-
diometabolic profile. If compared with the female control
population, this indication is even clearer. The differences
of adiponectin encountered might be due to differences
on fat distribution (which is known to differ between gen-
ders, with men having more visceral and less subcutane-
ous fat) as well as due to the effect of sex hormones, that
are involved in the metabolism of adipose tissue and fat
distribution. Our results may be due to increased visceral
fat in female control population (proportionately larger
than the male). However, when comparing the diabetic
female population with control female we found that
adiponectin levels are decreased in diabetic women, in
agreement with previous data [44], which is consistent
with the other results of our study that show a worse
cardiometabolic profile of women in the presence of
T2DM. The significant decrease of adiponectin levels in
diabetic men, when compared with control men, is con-
sistent with other studies which have previously suggested
that low adiponectin levels are associated with fatty liver
disease in women and low testosterone levels in men with
type 2 diabetes [45].
Diabetic women presented not only the expected in-
creased glycemia and obesity (higher BMI and WC)
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also increased hsCRP, TNF-α, uric acid and VEGF,
accompanied by reduced adiponectin. Additionally, des-
pite unchanged values of classical lipid profile (total-c,
LDL-c, non-HDL-c), due to medication, the diabetic fe-
males showed increased TGs and reduced HDL-c qual-
ity, confirmed by the reduced amount of large HDL-c
and increased of small HDL-c, regardless of normal total
HDL-c quantity. Low levels of HDL-c are a major CHD
risk factor in type 2 diabetic subjects [46]. In T2DM pa-
tients, TGs are usually elevated and HDL metabolism is
perturbed with evidence of both qualitative and quantita-
tive alterations [17]. Despite the growing body of evidence
indicating that determination of HDL subpopulations may
add an important information on CHD risk prediction
[15,18], data on HDL subpopulation distribution and its
modulating factors in women when compared with male
are limited, including in diabetic populations. Our data is
in agreement with the study of Russo et al. (2010) that
showed a lipid and HDL subpopulation profiles more
atherogenic in the diabetic women [47].
Some of the markers of cardiometabolic risk analyzed
showed important correlations in the female diabetic
population, in opposition with the data obtained in the
male one, reinforcing the previous data and indications.
Indeed, the waist circumference in the diabetic women
is positively and significantly correlated with the concen-
trations of hsCRP, TNF-α and VEGF, which was not en-
countered in the male diabetic individuals, for whom the
increased uric acid is indeed the best association with
waist circumference. Additionally, TNF-α contents are
positively and significantly correlated with VEGF levels
and hsCRP concentrations are inversely and significantly
correlated with adiponectin values. Collectively, this data
suggests that obesity, and especially abdominal adiposity,
in female diabetic subjects, is metabolically more active
and, consequently, deleterious than in male. This data is
in agreement with the fact that women with T2DM,
compared with age-matched non-diabetic women, ex-
hibit several-fold higher rates of death related to CAD,
with event rates nearly identical to those observed in
T2DM men [13], as is also in line with other study in
type 1 diabetes [48]. Our data suggested that diabetes
abrogate the protective effect of gender encountered in
women without diabetes, which agrees with the suggestion
that CHD risk is higher in men and that the difference is
reduced in diabetic populations [49]. Nevertheless, the
traditional CVRFs fail to completely explain these sex dif-
ferences, and the new “non-classical” factors seem to be
able to improve knowledge and clarify this discrepancies,
in particular the more atherogenic lipid sketch and pro-
inflammatory and pro-angiogenic profile, viewed mainly
by the contents of HDL-c subpopulations and the serum
values of TNF-α, hsCRP and VEGF.Regarding the influence of menopause, glycemia was
significantly higher after menopause, both for control
and diabetic females. However, postmenopausal diabetic
woman presented significantly increased BMI and waist
circumference when compared with the control post-
menopausal subjects, while no changes were observed
between groups at premenopausal stage. Systolic blood
pressure was significantly increased after menopause, for
both control and diabetic groups. However, diabetic pa-
tients presented a trend to reduced SBP and significantly
lower values of DBP, when compared with the control
population, both for pre and postmenopause compari-
sons, which might be due to antihypertensive medica-
tion. In relation to the classical lipid profile, in both the
2control and diabetic groups, no changes were encoun-
tered between pre and postmenopausal women for total-c,
TGs, LDL-c and non-HDL-c. Additionally, both pre and
postmenopausal diabetic patients presented unchanged or
even decrease (LDL-c) values for all of those parameters.
This profile is in agreement, again, with the type of
antidyslipidemic therapy practiced by those patients,
mainly statins, which decrease total-c and LDL-c contents,
but have less impact on TGs and HDL-c levels. Indeed,
TGs concentrations were significantly higher, but only in
the postmenopausal diabetic women when compared with
the control postmenopausal subjects. In addition, al-
though total HDL-c concentration was unchanged in pre
and postmenopausal diabetic women, when compared
with the control matched subpopulations, in the postmen-
opausal stage the HDL-c quality is worse, viewed by the
significantly reduced proportion of large HDL-c and in-
creased of small HDL-c. Although further studies are
needed to clarify the complex role of the different HDL
particles in the development of CHD, several lines of evi-
dence indicate that evaluating HDL subpopulations profile
may provide some adjunctive information on CHD risk
definition, independently from total HDL-c measurements
[15,18]. Our data clearly reinforces this recommendation,
in particular in the postmenopausal diabetic women, in
whom the quality of HDL is poor.
Concerning other markers of cardiovascular/metabolic
risk, before menopause the diabetic women presented
significantly increased hsCRP, uric acid and VEGF, with
a trend to reduced adiponectin contents, when com-
pared with the non-diabetic females. These changes were
maintained after the menopause, accompanied by in-
creased TNF-α concentration. In this population, an im-
portant association was found between some of the
markers of cardiometabolic risk. Indeed, the waist cir-
cumference in the postmenopausal diabetic women is
positively and significantly correlated with the concentra-
tions of hsCRP, TNF-α and VEGF. Additionally, TNF-α
contents are positively and significantly correlated with
VEGF levels, hsCRP concentrations are inversely and
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nally, uric acid was inversely and significantly correlated
with large HDL-c. Thus, the postmenopausal diabetic
females have an increased obesity which seems to be
metabolically more deleterious than in premenopausal
diabetic women, namely due to obesity-induced low-
degree chronic inflammation, through enhanced adipose
tissue-derived cytokine expression, in agreement with
previous recent reports [50]. The transition from pre to
postmenopause may be associated with features of the
metabolic syndrome, including an increased central
body fat, a shift toward a more atherogenic lipid profile,
as well as other risk factors. Obesity is an independent
risk factor for macrovascular disease across sexes, but
despite higher incidence of obesity in premenopausal
women, rates of macrovascular disease are lower in
premenopausal women than in men. Interestingly, this
sex difference, which normally vanishes after meno-
pause, is rapidly lost in premenopausal DM patients,
with CVD reaching 2- to 5-fold higher rates than in
non-diabetic women [12]. In fact, women with T2DM,
compared with age-matched non-diabetic women, ex-
hibit significantly higher rates of death related to CAD,
similar to those observed in T2DM men [13]. The emer-
gence of the CVD risk factors in the postmenopausal
women may be a direct result of ovarian failure, or an
indirect result of the metabolic consequences of body
fat centralization with estrogen deficiency. Previous
studies have also demonstrated that menopause is associ-
ated with a modest increase in total fatness and an accel-
erated accumulation of central body fat that exceeds
changes normally attributed to the aging process [30,51].
Similarly in our studies, postmenopausal women, when
compared to premenopausal women, had a higher WC,
TGs level and other non classical markers, suggesting an
increased CV risk. Previous reports have indicated that
the diabetic postmenopausal women have more severe
CAD and CV risk compared to non-diabetic women [52].
Although the small number of premenopausal dia-
betic women could be viewed as a study limitation, that
deserves further strengthening, postmenopausal dia-
betic women have a clearly poor cardiometabolic profile
since several parameters that are unchanged between
premenopausal diabetic subjects when compared with
the premenopausal controls, are aggravated in the post-
menopausal diabetic ones, versus the corresponding
postmenopausal controls, including significantly in-
creased TGs, small HDL, WC, BMI and TNF-α values,
aggravated contents of VEGF and uric acid, significantly
lower of large HDL and a trend to reduced adiponectin
concentration. Collectively, our data reinforces the sug-
gestion that the multi-targeted treatment of all risk fac-
tors is even more justified in postmenopausal women,
which is mainly suggested by non-traditional markers inthis diabetic population medicated for hypertension and
dyslipidemia. The apparently more deleterious visceral
obesity, the more atherogenic lipid sketch and the pro-
inflammatory profile in diabetic patients in general, but in
the postmenopausal women in particular, urges precise at-
tention and proper multi-therapeutic intervention.
Conclusions
Our study suggests that diabetes abrogate the protective
effect of female gender on non-diabetic subjects when
compared with male, and that postmenopausal diabetic
females presented worsen cardiometabolic profile, in-
cluding a more atherogenic lipid sketch and a pro-
inflammatory and pro-angiogenic profile. The traditional
CVRFs fail to completely explain these differences,
which are better clarified using “non-classical” markers,
such as contents of HDL-c subpopulations, rather than
total content, and mediators of inflammation and angio-
genesis, namely TNF-α, hsCRP, uric acid and VEGF.
Multi-therapeutic intervention, directed to obesity,
atherogenic lipid particles and inflammatory mediators,
is advisory in order to efficiently prevent the serious car-
diovascular complications of diabetes in this higher-risk
population.
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